Table 5. SGLT2 inhibitor trials in HF with reduced EF.

Clinical trial (patients enrolled)	Drug/Target daily dose	Entry criteria	Background therapy (%)	Outcomes
EMPORER Reduced (n=3,730)	Empagliflozin 10 mg daily vs. placebo	Symptomatic HF with EF ≤35% regardless of diabetic status	ACE inhibitor/ARB (70%), ARNI (20%), MRA (71%), beta blocker (95%)	Combined CV death and HF hospitalization reduced by 25% (p<0.001); HF hospitalizations reduced by 30% (p<0.001)†
DAPA-HF (n=4,744)	Dapagliflozin 10 mg daily vs. placebo	Symptomatic HF with EF ≤0.40 regardless of diabetic status	Diuretic (93%), ACE inhibitor/ARB (84%), ARNI (11%), MRA (71%), beta blocker (96%), digitalis (19%)	Combined worsening HF or CV death was reduced by 26% (p<0.001); worsening HF event was reduced by 30%; CV death was reduced by 18%†
SOLOIST (n=1,222)	Sotagliflozin* 400 mg daily vs. placebo	Recent HF hospitalization and type 2 diabetes with 49% started in hospital	Loop diuretic (95%), ACE inhibitor/ARB (82%), ARNI (17%), beta blocker (92%), MRA (65%)	Combined CV death and HF events (first and subsequent) was reduced by 33% (p<0.001), CV death was reduced by 16%, all-cause death was reduced by 18%

ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; CV = cardiovascular; EF = ejection fraction; HF = heart failure; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; SGLT = sodium glucose cotransporter.

^*Sotagliflozin is a combined SGLT1 and SGLT2 inhibitor; ^†Benefits seen regardless of diabetic status.